Active, not recruitingPhase 2NCT04071223
Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
Studying Chromophobe renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Rana R McKay, MDAlliance for Clinical Trials in Oncology
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 134 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- UC San Diego Moores Cancer Center, La Jolla, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Rush MD Anderson Cancer Center, Chicago, Illinois, United States
- University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
- Cancer Care Specialists of Illinois - Decatur, Decatur, Illinois, United States
- Loyola University Medical Center, Maywood, Illinois, United States
- UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois, United States
- Rush MD Anderson Cancer Center at Rush Oak Park, Oak Park, Illinois, United States
- University of Chicago Medicine-Orland Park, Orland Park, Illinois, United States
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny, Iowa, United States
- Iowa Methodist Medical Center, Des Moines, Iowa, United States
- UI Health Care Mission Cancer and Blood - Des Moines Clinic, Des Moines, Iowa, United States
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
- University of Kansas Cancer Center, Kansas City, Kansas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04071223 on ClinicalTrials.govOther trials for Chromophobe renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07485114Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 InhibitorsDaniel Keizman
- RECRUITINGPHASE3NCT07227402A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07233252Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic CancerTianjin Medical University Second Hospital
- RECRUITINGNANCT07171190Targeted Abdominal CT in Conjunction With Lung Cancer ScreeningUniversity of Cambridge
- RECRUITINGPHASE2NCT07050771Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer SurgeryThe Methodist Hospital Research Institute
- RECRUITINGPHASE2NCT06642220Ablative Radioembolization of Renal Cell Carcinoma TrialDerek W. Cool
- RECRUITINGNCT06889974Timing of Renal Replacement Therapy Initiation in Tumor Lysis SyndromeUniversity Hospital, Bordeaux
- ENROLLING BY INVITATIONNCT07307157Head-to-Head Evaluation of the Cancer Ontology Supervised Multimodal Orchestration (COSMO) AI System Versus Pathologist-Only ReviewHarvard Medical School (HMS and HSDM)